Module 20 · Neuro-critical care

Neuro emergencies

NewPhase 1

Time-critical neurological emergencies in the ICU: the status epilepticus ladder, acute ischaemic stroke and thrombolysis, intracerebral and subarachnoid haemorrhage, a structured approach to coma, CNS infections, and neuromuscular respiratory failure (GBS and myasthenic crisis).

6 topics

Drugs in this module

Doses written for this module's context. The same drug may read differently in another module.

Lorazepam

Benzodiazepine

Indications
First-line for status epilepticus.
Adult dose
0.1 mg/kg IV (max 4 mg per dose) at 2 mg/min, repeat once after 5-10 min.
Preparation (India)
2 mg/mL ampoules; needs refrigeration.
Cautions
Respiratory depression, hypotension; under-dosing is the commonest error.

Midazolam

Benzodiazepine

Indications
First-line SE without IV access (IM/buccal); refractory SE infusion.
Adult dose
IM 10 mg (> 40 kg) or 5 mg (13-40 kg) once. Refractory SE: 0.2 mg/kg IV bolus, then 0.05-2 mg/kg/h titrated to seizure/EEG suppression.
Preparation (India)
1 mg/mL and 5 mg/mL ampoules.
Cautions
Accumulates in renal failure and obesity; hypotension.

Levetiracetam

Antiseizure medication

Indications
Second-line for established SE; seizure prophylaxis.
Adult dose
60 mg/kg IV (max 4500 mg) over 10-15 min; maintenance 1-1.5 g every 12 h (reduce in renal impairment).
Preparation (India)
500 mg/5 mL vials.
Cautions
Agitation; renally cleared (dose adjust in AKI/CRRT).

Sodium valproate

Antiseizure medication

Indications
Second-line for established SE.
Adult dose
40 mg/kg IV (max 3000 mg) over 10 min; maintenance 1-2 g/day in divided doses.
Preparation (India)
100 mg/mL 5 mL vials.
Cautions
Avoid in liver disease, mitochondrial disorders, pregnancy if alternatives exist; hyperammonaemia; interacts with carbapenems (levels fall sharply).

Phenytoin

Antiseizure medication

Indications
Second-line for established SE.
Adult dose
20 mg/kg IV at ≤ 50 mg/min (≤ 25 mg/min in elderly/cardiac) in 0.9% saline; maintenance 100 mg every 8 h guided by levels. Fosphenytoin 20 mg PE/kg at up to 150 mg PE/min where available.
Preparation (India)
50 mg/mL ampoules; precipitates in dextrose.
Cautions
Hypotension, bradyarrhythmia (ECG monitoring), purple glove syndrome; many interactions.

Tenecteplase

Thrombolytic

Indications
Acute ischaemic stroke within 4.5 h (or selected later windows).
Adult dose
0.25 mg/kg IV single bolus (max 25 mg).
Preparation (India)
Indian biosimilar tenecteplase 20 mg and 30 mg vials are available.
Cautions
Different dose from STEMI (do not use the cardiac weight-band dose). BP must be < 185/110.

Alteplase

Thrombolytic

Indications
Acute ischaemic stroke within 4.5 h.
Adult dose
0.9 mg/kg (max 90 mg): 10% IV bolus over 1 min, remainder over 60 min.
Cautions
Angio-oedema (especially with ACE inhibitors), bleeding.

Nimodipine

Calcium channel blocker

Indications
Aneurysmal SAH (improves outcome).
Adult dose
60 mg orally/NG every 4 h for 21 days (30 mg every 2 h if hypotension).
Cautions
Hypotension: reduce dose and split rather than stop.

Ceftriaxone

Third-generation cephalosporin

Indications
Empirical bacterial meningitis.
Adult dose
2 g IV every 12 h (meningitic dose).
Cautions
Biliary sludge; calcium co-infusion in neonates.

Dexamethasone

Corticosteroid

Indications
Suspected bacterial meningitis (start with or before first antibiotic dose).
Adult dose
10 mg IV every 6 h for 4 days; stop if not pneumococcal/Haemophilus or if non-bacterial.
Cautions
Hyperglycaemia; reduces vancomycin CSF penetration.

Aciclovir

Antiviral

Indications
Suspected HSV/VZV encephalitis.
Adult dose
10 mg/kg IV every 8 h for 14-21 days (adjust for renal function; use ideal body weight in obesity).
Cautions
Crystal nephropathy: hydrate, monitor creatinine.

Intravenous immunoglobulin (IVIg)

Immunomodulator

Indications
GBS (unable to walk unaided); myasthenic crisis.
Adult dose
0.4 g/kg/day for 5 days (total 2 g/kg).
Preparation (India)
5 g and 10 g vials; very costly; check IgA deficiency if possible.
Cautions
Thrombosis, AKI (sucrose-containing products), aseptic meningitis, volume load.

Module references (13)

  1. 1

    Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus (ESETT). N Engl J Med. 2019;381(22):2103-2113

  2. 2

    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23

  3. 3

    Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61

  4. 4

    Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2026;57(8):e316-e436

  5. 5

    Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361

  6. 6

    Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314-e370

  7. 7

    Wijdicks EFM, Bamlet WR, Maramattom BV, Manno EM, McClelland RL. Validation of a new coma scale: the FOUR score. Ann Neurol. 2005;58(4):585-593

  8. 8

    van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37-S62

  9. 9

    de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549-1556

  10. 10

    Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303-327

  11. 11

    van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023;30(12):3646-3674

  12. 12

    Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781-787

  13. 13

    Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122